Get started
Author

Nicholas Pemberton

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
2023 · Talha Munir, David A. Cairns, et al. · New England Journal of Medicine · 179
PDF
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
2023 · Peter Hillmen, Alexandra Pitchford, et al. · The Lancet Oncology · 115
PDF
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia
2025 · Talha Munir, Sean Girvan, et al. · New England Journal of Medicine · 48
PDF
Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial
2021 · Peter Hillmen, Alexandra Pitchford, et al. · Blood · 36
PDF
Diagnostic uncertainty presented barriers to the timely management of acute thrombotic thrombocytopenic purpura in the United Kingdom between 2014 and 2019
2022 · Tom P. Bull, Rory McCulloch, et al. · Journal of Thrombosis and Haemostasis · 24
PDF
The SDF-1 G > A polymorphism at position 801 plays no role in multiple myeloma but may contribute to an inferior cause-specific survival in chronic lymphocytic leukemia
2006 · N. C. Pemberton, S. Paneesha, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 20
Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial
2021 · Talha Munir, Alexandra Pitchford, et al. · Blood · 15
Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study
2023 · Peter Hillmen, David Allan Cairns, et al. · Blood · 11
Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study
2022 · Talha Munir, Alexandra Pitchford, et al. · Blood · 10
CPX-351 for Acute Myeloid Leukaemia: Real World Results Are Comparable to Trial Outcomes and Exceeds Them in Non-Adverse Risk Patients- a Multicentre Experience from West Midlands Hospitals on Behalf of West Midlands Research Consortium ( WMRC) UK
2021 · Vidhya Murthy, Richard Whitmill, et al. · Blood · 8
S145: the Combination of Ibrutinib Plus Venetoclax Results in a High Rate of Mrd Negativity in Previously Untreated Cll: the Results of the Planned Interim Analysis of the Phase Iii Ncri Flair Trial
2022 · P. Hillmen, A. Pitchford, et al. · HemaSphere · 7
IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study
2024 · Talha Munir, Abraham Mullasseril Varghese, et al. · Blood · 5
PDF
Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the UK National Cancer Research Institute phase II / III GALACTIC trial
2022 · Talha Munir, Jake Emmerson, et al. · British Journal of Haematology · 4
PDF
In situ follicular neoplasia with translocation of BCL6 – a new variant with different immunohistochemical properties
2021 · Zbigniew Rudzki, Jane Starczynski, et al. · British Journal of Haematology
PDF
Obinutuzumab As Consolidation after Chemo-Immunotherapy Is Highly Effective in Achieving MRD Clearance from Bone Marrow and Peripheral Blood- Initial Results of UK NCRI Phase II/III Galactic Trial
2017 · Talha Munir, Peter Hillmen, et al. · White Rose Research Online (University of Leeds, The University of Sheffield, University of York)
Works count: 15
Citation count: 482
H-index: 9
I10-index: 9
Year
Topic
Type